Schedule of Segment Reporting Information |
The CODM evaluates segment performance based on revenue and adjusted gross profit. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | 2025 | | 2024 | | GeneDx | | Other | | Total | | GeneDx | | Other | | Total | Revenue | $ | 101,784 | | | $ | 908 | | | $ | 102,692 | | | $ | 68,924 | | | $ | 1,590 | | | $ | 70,514 | | Adjusted cost of services | 29,964 | | | 244 | | | 30,208 | | | 26,523 | | | 145 | | | 26,668 | | Adjusted gross profit (1) | 71,820 | | | 664 | | | 72,484 | | | 42,401 | | | 1,445 | | | 43,846 | | | | | | | | | | | | | | Reconciliations: | | | | | | | | | | | | Depreciation and amortization | | | | | 1,389 | | | | | | | 808 | | Stock-based compensation | | | | | 193 | | | | | | | 86 | | | | | | | | | | | | | | Gross profit | | | | | $ | 70,902 | | | | | | | $ | 42,952 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Six months ended June 30, | | 2025 | | 2024 | | GeneDx | | Other | | Total | | GeneDx | | Other | | Total | Revenue | $ | 188,899 | | | $ | 908 | | | $ | 189,807 | | | $ | 130,385 | | | $ | 2,551 | | | $ | 132,936 | | Adjusted cost of services | 57,360 | | | 244 | | | 57,604 | | | 50,622 | | | 145 | | | 50,767 | | Adjusted gross profit (1) | 131,539 | | | 664 | | | 132,203 | | | 79,763 | | | 2,406 | | | 82,169 | | | | | | | | | | | | | | Reconciliations: | | | | | | | | | | | | Depreciation and amortization | | | | | 2,464 | | | | | | | 1,624 | | Stock-based compensation | | | | | 361 | | | | | | | 134 | | Restructuring costs | | | | | — | | | | | | | 48 | | Gross profit | | | | | $ | 129,378 | | | | | | | $ | 80,363 | |
(1)Adjusted cost of services and adjusted gross profit exclude depreciation and amortization expense, stock-based compensation expense and restructuring costs.
|